Apellis and Sobi’s Empaveli clinches FDA approval for rare kidney diseasesnews2025-07-29T08:25:34+00:00July 29th, 2025|Endpoints News|
Sarepta to resume shipping Duchenne therapy after FDA reversalnews2025-07-28T21:03:04+00:00July 28th, 2025|Endpoints News|
FDA investigates death of boy who got Elevidys, Roche says death unrelated to therapynews2025-07-26T09:32:16+00:00July 26th, 2025|Endpoints News|
FDA delays decision date on Bayer’s hot flash drugnews2025-07-25T19:20:37+00:00July 25th, 2025|Endpoints News|
FDA developing new flu vaccine framework to tackle ‘problems,’ senior official saysnews2025-07-25T19:08:08+00:00July 25th, 2025|Endpoints News|
CHMP backs Lilly’s Alzheimer’s drug in certain patients, Gilead’s twice-yearly HIV prevention shot, among othersnews2025-07-25T15:17:24+00:00July 25th, 2025|Endpoints News|
How Sarepta’s crisis over patient deaths unfolded, and what happens nextnews2025-07-24T18:13:51+00:00July 24th, 2025|Endpoints News|
Sarepta would have to conduct new studies to get back on market, FDA official saysnews2025-07-24T15:17:46+00:00July 24th, 2025|Endpoints News|
Political or professional? Makary’s overhaul of CDER, CBER may reshape leadership normsnews2025-07-23T17:13:15+00:00July 23rd, 2025|Endpoints News|
FDA delays review date for GSK’s multiple myeloma drug Blenrepnews2025-07-23T16:42:28+00:00July 23rd, 2025|Endpoints News|
